Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Description

The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.

Conditions

Netherton Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351, and to observe treatment benefits of the drug in approximately 12 adult patients with Netherton Syndrome (NS). ATR12-351 will be applied to skin lesions on one side of the body, while the vehicle control will be applied to similar lesion on the other side of the body twice daily for 2 weeks.

A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome

Condition
Netherton Syndrome
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale University, New Haven, Connecticut, United States, 06519

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adults ≥18 years of age
  • * Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene
  • * Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome
  • * Use of biologic therapies, antibiotics, antihistamines, corticosteroids, retinoids, disease-modifying antirheumatic drugs (DMARDs), immunosuppressive agents, phosphodiesterase-4 (PDE4) inhibitors, topical calcineurin inhibitors, or topical Janus kinase (JAK) inhibitors
  • * Open wounds or extensive areas of excoriation precluding identification of appropriate application sites in the Investigator's judgment
  • * Concurrent involvement in any other clinical study/expanded access program with an investigational drug or device or has participated in a clinical study within 30 days prior to the screening visit
  • * Residing with an immunocompromised person in the same dwelling from the baseline visit through 2 weeks after the treatment period
  • * History of ultraviolet phototherapy within the planned treatment area 4 weeks prior to baseline

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Azitra Inc.,

Mary Spellman, MD, STUDY_DIRECTOR, Azitra Inc.

Study Record Dates

2025-08-01